JY BioMed Showcases Regenerative Medicine Breakthroughs at Vietnam’s Largest National Medical Conference

Binh Duong, Vietnam – July 26, 2025 – JY BioMed’s Chief Medical Officer, Dr. Benjamin Zhang, was invited as a keynote speaker at Vietnam’s largest cross-hospital medical conference, hosted by the nation’s leading public hospital alliance. The event, held at the World Trade Exhibition Center in Binh Duong Province, gathered over 1,000 physicians and nurses from across the country.

The 2025 conference was jointly organized by Hanoi Medical University Hospital, Binh Duong General Hospital, Da Nang General Hospital, Gia Lai General Hospital, and Ha Giang General Hospital in Tuyen Quang Province, representing the pinnacle of Vietnam’s public healthcare system. Dr. Zhang joined an elite panel of international experts, including Prof. Wu-Hsiu Chang from Show Chwan Healthcare System, Dr. Ching-Tsung Tseng from AIM (Asia’s leader in AI medical diagnostics), and specialists from the National University Hospital of Singapore.

Presenting the Future of Postoperative Recovery

In his session titled “Clinical-Grade UC-MSC & Exosomes for Enhanced Surgical Recovery”, Dr. Zhang introduced JY BioMed’s latest advancements in regenerative medicine. The talk highlighted how umbilical cord-derived mesenchymal stem cell (UC-MSC) exosomes can address the three critical barriers in postoperative recovery:

• Excessive inflammation

• Delayed tissue healing

• Postoperative pain

Drawing on peer-reviewed studies and JY BioMed’s proprietary data, Dr. Zhang demonstrated how UC-MSC exosomes deliver anti-inflammatory, neuroprotective, and tissue-repair functions, supported by both animal model research and real-world clinical insights. The presentation also outlined JY BioMed’s U.S. FDA IND and DMF filings, underscoring the company’s readiness for global clinical integration.

Strengthening Taiwan–Vietnam Medical Collaboration

Dr. Zhang emphasized JY BioMed’s commitment to international translational medicine partnerships, inviting Vietnam’s medical community to join in clinical research collaborations. This initiative aligns with Taiwan’s New Southbound Policy, promoting deeper healthcare innovation ties between Taiwan and Vietnam.

“Postoperative recovery still faces major challenges,” said Dr. Zhang. “UC-MSC-derived exosomes may offer a safe, scalable, and cell-free therapeutic option that can transform surgical outcomes and improve patient quality of life worldwide.”

About JY BioMed

JY BioMed is a Taiwan-based biotechnology company at the forefront of cell therapy, exosome therapeutics, and immune oncology. With cutting-edge facilities and a strong international network, JY BioMed is advancing novel treatments from biological innovation to clinical transformation, addressing some of the most pressing unmet medical needs globally.